Cargando…

Defining criteria for the introduction of liraglutide using the glucagon stimulation test in patients with type 2 diabetes

AIMS/INTRODUCTION: To define a set of criteria using indices of β‐cell function, including results from the glucagon stimulation test, for liraglutide introduction in patients with type 2 diabetes. MATERIALS AND METHODS: In the present retrospective cohort study, patients were included in our analys...

Descripción completa

Detalles Bibliográficos
Autores principales: Kondo, Yoshinobu, Satoh, Shinobu, Nagakura, Joe, Kimura, Masayo, Nezu, Uru, Terauchi, Yasuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley-Blackwell 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4020252/
https://www.ncbi.nlm.nih.gov/pubmed/24843711
http://dx.doi.org/10.1111/jdi.12082
_version_ 1782316038063390720
author Kondo, Yoshinobu
Satoh, Shinobu
Nagakura, Joe
Kimura, Masayo
Nezu, Uru
Terauchi, Yasuo
author_facet Kondo, Yoshinobu
Satoh, Shinobu
Nagakura, Joe
Kimura, Masayo
Nezu, Uru
Terauchi, Yasuo
author_sort Kondo, Yoshinobu
collection PubMed
description AIMS/INTRODUCTION: To define a set of criteria using indices of β‐cell function, including results from the glucagon stimulation test, for liraglutide introduction in patients with type 2 diabetes. MATERIALS AND METHODS: In the present retrospective cohort study, patients were included in our analysis if their β‐cell function had been evaluated with a glucagon stimulation test and a 24‐h urinary C‐peptide (U‐CPR) excretion test before switching from insulin therapy to liraglutide monotherapy. The efficacy of liraglutide was determined by the extent to which glycemic control was achieved or if glycated hemoglobin levels were maintained at <7.0% after liraglutide monotherapy for 24 weeks. RESULTS: Liraglutide was effective in 36 of 77 patients. In the liraglutide‐effective cases, the following parameters were higher: fasting C‐peptide (CPR0) levels, C‐peptide levels 6 min after glucagon stimulation (CPR6), the C‐peptide index (CPI; CPR0 × 100/fasting plasma glucose) and stimulated C‐peptide index (S‐CPI; CPR6 × 100/plasma glucose 6 min after glucagon stimulation). U‐CPR did not differ between liraglutide‐effective and liraglutide‐ineffective cases. Using receiver operating characteristic analysis adjusted for baseline characteristics, the independent cut‐off value for effective liraglutide introduction was 0.72 for CPI and 1.92 for S‐CPI. CONCLUSIONS: Evaluation of β‐cell function using the glucagon stimulation test is useful for determining the efficacy of liraglutide introduction in patients with type 2 diabetes.
format Online
Article
Text
id pubmed-4020252
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Wiley-Blackwell
record_format MEDLINE/PubMed
spelling pubmed-40202522014-05-19 Defining criteria for the introduction of liraglutide using the glucagon stimulation test in patients with type 2 diabetes Kondo, Yoshinobu Satoh, Shinobu Nagakura, Joe Kimura, Masayo Nezu, Uru Terauchi, Yasuo J Diabetes Investig Articles AIMS/INTRODUCTION: To define a set of criteria using indices of β‐cell function, including results from the glucagon stimulation test, for liraglutide introduction in patients with type 2 diabetes. MATERIALS AND METHODS: In the present retrospective cohort study, patients were included in our analysis if their β‐cell function had been evaluated with a glucagon stimulation test and a 24‐h urinary C‐peptide (U‐CPR) excretion test before switching from insulin therapy to liraglutide monotherapy. The efficacy of liraglutide was determined by the extent to which glycemic control was achieved or if glycated hemoglobin levels were maintained at <7.0% after liraglutide monotherapy for 24 weeks. RESULTS: Liraglutide was effective in 36 of 77 patients. In the liraglutide‐effective cases, the following parameters were higher: fasting C‐peptide (CPR0) levels, C‐peptide levels 6 min after glucagon stimulation (CPR6), the C‐peptide index (CPI; CPR0 × 100/fasting plasma glucose) and stimulated C‐peptide index (S‐CPI; CPR6 × 100/plasma glucose 6 min after glucagon stimulation). U‐CPR did not differ between liraglutide‐effective and liraglutide‐ineffective cases. Using receiver operating characteristic analysis adjusted for baseline characteristics, the independent cut‐off value for effective liraglutide introduction was 0.72 for CPI and 1.92 for S‐CPI. CONCLUSIONS: Evaluation of β‐cell function using the glucagon stimulation test is useful for determining the efficacy of liraglutide introduction in patients with type 2 diabetes. Wiley-Blackwell 2013-04-26 2013-11-27 /pmc/articles/PMC4020252/ /pubmed/24843711 http://dx.doi.org/10.1111/jdi.12082 Text en Copyright © 2013 Asian Association for the Study of Diabetes and Wiley Publishing Asia Pty Ltd
spellingShingle Articles
Kondo, Yoshinobu
Satoh, Shinobu
Nagakura, Joe
Kimura, Masayo
Nezu, Uru
Terauchi, Yasuo
Defining criteria for the introduction of liraglutide using the glucagon stimulation test in patients with type 2 diabetes
title Defining criteria for the introduction of liraglutide using the glucagon stimulation test in patients with type 2 diabetes
title_full Defining criteria for the introduction of liraglutide using the glucagon stimulation test in patients with type 2 diabetes
title_fullStr Defining criteria for the introduction of liraglutide using the glucagon stimulation test in patients with type 2 diabetes
title_full_unstemmed Defining criteria for the introduction of liraglutide using the glucagon stimulation test in patients with type 2 diabetes
title_short Defining criteria for the introduction of liraglutide using the glucagon stimulation test in patients with type 2 diabetes
title_sort defining criteria for the introduction of liraglutide using the glucagon stimulation test in patients with type 2 diabetes
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4020252/
https://www.ncbi.nlm.nih.gov/pubmed/24843711
http://dx.doi.org/10.1111/jdi.12082
work_keys_str_mv AT kondoyoshinobu definingcriteriafortheintroductionofliraglutideusingtheglucagonstimulationtestinpatientswithtype2diabetes
AT satohshinobu definingcriteriafortheintroductionofliraglutideusingtheglucagonstimulationtestinpatientswithtype2diabetes
AT nagakurajoe definingcriteriafortheintroductionofliraglutideusingtheglucagonstimulationtestinpatientswithtype2diabetes
AT kimuramasayo definingcriteriafortheintroductionofliraglutideusingtheglucagonstimulationtestinpatientswithtype2diabetes
AT nezuuru definingcriteriafortheintroductionofliraglutideusingtheglucagonstimulationtestinpatientswithtype2diabetes
AT terauchiyasuo definingcriteriafortheintroductionofliraglutideusingtheglucagonstimulationtestinpatientswithtype2diabetes